Latest from Clara Ashworth

Markets
Zura Bio (ZURA) said its experimental drug failed the main goal of a mid-stage study in patients with hidradenitis suppurativa, a chronic skin disease that causes painful lumps under the skin. Shares in the biotech group fell more than 75…
20 Nov 2026 
Business
Swiss drug developer Windward Bio is targeting a valuation of up to $1bn in its US initial public offering, as a strong run for the biotech listings market extends into November.
The Basel-based company is seeking to raise up to…
17 Nov 2026 
Deals
AstraZeneca (AZN) made an offer of about $10bn to acquire obesity drugmaker Rhythm Pharmaceuticals (RYTM), according to three people familiar with the matter.
16 Nov 2026 Business
Sanofi (SNY) is prepared to pursue larger acquisitions as it seeks to rebuild its pipeline of experimental drugs under new chief executive Belen Garijo, after the French drugmaker raised its 2026 growth targets for the second time this…
10 Nov 2026 Business
AstraZeneca (AZN) unveiled plans to save about $1.5bn a year to invest in its drug pipeline. The announcement sparked the stock’s biggest one-day rally in a year, as chief executive Pascal Soriot moved to shift the focus back to growth…
10 Nov 2026 Deals
Surgery Partners (SGRY) will be taken private by HealthSpan Partners, an affiliate of nonprofit hospital system Bon Secours Mercy Health, in a deal valued at about $5.7bn including debt. Shares in the outpatient surgery operator rose 46…
6 Nov 2026 Deals
Zealand Pharma (ZELA) has partnered with US biotech Generate Biomedicines (GENB) to develop protein-based treatments for obesity and other metabolic diseases using artificial intelligence, in a deal worth up to $1.2bn.
29 Oct 2026 Deals
AstraZeneca (AZN) has teamed up with artificial intelligence biotech insitro to discover and develop treatments for liver and heart conditions that have proved hard to treat, the British drugmaker said.
29 Oct 2026 Deals
Swiss skincare company Galderma (GALD) has agreed to acquire US group ZO Skin Health for an enterprise value of $1.5bn, confirming an earlier Reuters report. The purchase of the Irvine, California-based company is Galderma's largest since…
24 Oct 2026 Business
GSK (GSK) will invest more than $800mn to expand its Upper Merion, Pennsylvania, site into a new biopharmaceutical manufacturing and research hub, creating more than 300 jobs over the next five years, the office of Pennsylvania Governor…
22 Oct 2026 Deals
Steris (STE) will buy privately held Xodus Medical for $2.1bn, adding surgical products designed to improve safety for patients and operating-room staff to its healthcare consumables business.
20 Oct 2026 Deals
Viatris (VTRS) has agreed to buy Pacira BioSciences (PCRX) for $1.65bn in cash. The deal adds two non-opioid pain treatments to its portfolio as the drugmaker tries to build out higher-value branded medicines beyond its core generics…
19 Oct 2026 Business
BioMarin Pharmaceutical (BMRN) is cutting 117 jobs at its Novato, California, site, just months after trimming staff in New Jersey following an acquisition.
16 Oct 2026 Business
Bayer (BAYN) is to invest $2.2bn in a new manufacturing site in New Albany, Ohio, as its pharmaceuticals division seeks to increase its revenue in the US.
16 Oct 2026 Business
BridgeBio (BBIO), the maker of Attruby, is relaunching its "Don't Pass on Your Heart Health" campaign with a new approach, as it seeks to close the awareness gap around transthyretin amyloid cardiomyopathy (ATTR-CM).
15 Oct 2026 Deals
CSL (CSL.AX) has agreed to co-develop and co-promote an experimental treatment for rare kidney and liver diseases with Swiss drugmaker Alentis Therapeutics, in a deal worth up to $1.6bn, excluding development funding.
14 Oct 2026 Deals
Sanofi (SAN) and Regeneron (REGN) have agreed to develop four new drugs together in a deal worth up to $8bn and to settle prior litigation, a move analysts said signals a reset of their strained partnership and an early victory for…
13 Oct 2026 Deals
Novartis (NOVN) has agreed a licensing deal worth up to $7.8bn with China's Abogen to develop therapies based on messenger RNA, underscoring the Swiss drugmaker's growing interest in an emerging class of treatments.
11 Oct 2026 Deals
Roche (RHHBY) has agreed a deal with Atavistik Bio worth almost $2bn, including milestone payments, to develop oral treatments for cardiovascular, kidney and metabolic diseases.
9 Oct 2026 Deals
InnoCare Pharma (688428.SS) has signed a research collaboration and licensing agreement with Eli Lilly (LLY) worth up to about $3.35bn, the Chinese drugmaker announced.
9 Oct 2026